API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

11

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Also known as: Sunvozertinib [inn], L1q2k5jyo8, 2370013-12-8, Dzd9008, 2-propenamide, n-(5-((4-((5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl)amino)-2-pyrimidinyl)amino)-2-((3r)-3-(dimethylamino)-1-pyrrolidinyl)-4-methoxyphenyl)-, Unii-l1q2k5jyo8

Molecular Formula

C₂₉H₃₅ClFN₇O₃

Molecular Weight

584.1 g/mol

InChI Key

BTMKEDDEMKKSEF-QGZVFWFLSA-N

FDA UNII

L1Q2K5JYO8

Sunvozertinib is an orally available, irreversible, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) that shows similar activity against certain activating mutations, including exon 20 insertions (exon20ins), with potential antineoplastic activity. Upon oral administration,sunvozertinib binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization. In contrast to other agents active against exon20ins mutations, sunvozertinib appears to be more selective against mutated EGFR than wild-type (wt) EGFR. This may lessen wtEGFR-related dose-limiting toxicity and may allow for the administration of the desired therapeutic dose of sunvozertinib.

1 2D Structure

Sunvozertinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide

2.1.2 InChI

InChI=1S/C29H35ClFN7O3/c1-7-27(39)34-22-14-23(25(41-6)15-24(22)38-11-9-17(16-38)37(4)5)35-28-32-10-8-26(36-28)33-21-13-19(30)20(31)12-18(21)29(2,3)40/h7-8,10,12-15,17,40H,1,9,11,16H2,2-6H3,(H,34,39)(H2,32,33,35,36)/t17-/m1/s1

2.1.3 InChI Key

BTMKEDDEMKKSEF-QGZVFWFLSA-N

2.1.4 Canonical SMILES

CC(C)(C1=CC(=C(C=C1NC2=NC(=NC=C2)NC3=C(C=C(C(=C3)NC(=O)C=C)N4CCC(C4)N(C)C)OC)Cl)F)O

2.1.5 Isomeric SMILES

CC(C)(C1=CC(=C(C=C1NC2=NC(=NC=C2)NC3=C(C=C(C(=C3)NC(=O)C=C)N4CC[C@H](C4)N(C)C)OC)Cl)F)O

2.2 Other Identifiers

2.2.1 UNII

L1Q2K5JYO8

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Sunvozertinib [inn]

2. L1q2k5jyo8

3. 2370013-12-8

4. Dzd9008

5. 2-propenamide, N-(5-((4-((5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl)amino)-2-pyrimidinyl)amino)-2-((3r)-3-(dimethylamino)-1-pyrrolidinyl)-4-methoxyphenyl)-

6. Unii-l1q2k5jyo8

7. Schembl21232131

8. Gtpl11672

9. Glxc-25829

10. Ex-a6612

11. Example 52 [wo2019149164a1]

12. Hy-132842

13. Cs-0204146

14. N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide

2.4 Create Date

2019-11-02

3 Chemical and Physical Properties

Molecular Formula	C₂₉H₃₅ClFN₇O₃
Molecular Weight	584.1 g/mol
XLogP3	5
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	10
Exact Mass	583.2473939 g/mol
Monoisotopic Mass	583.2473939 g/mol
Topological Polar Surface Area	115 Å²
Heavy Atom Count	41
Formal Charge	0
Complexity	885
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1